Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

Yuna Suzuki; Wu Wenwen; Tomohiko Ohta; Shin ichi Hayashi

ArticleOPEN ACCESS

Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

Suzuki Y
Wenwen W
Ohta T
et al.

Breast Cancer

DOI: 10.1007/s12282-021-01288-z

0Citations

6Readers

Abstract

In the original publication of the article, the funding information should be revised as below. Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation.

Cite

CITATION STYLE

APA

Suzuki, Y., Wenwen, W., Ohta, T., & Hayashi, S. ichi. (2022, January 1). Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5). Breast Cancer. Springer Japan. https://doi.org/10.1007/s12282-021-01288-z

Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

Abstract

Cite

Register to see more suggestions